注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Lyra Therapeutics Inc是一家临床阶段的治疗公司,专注于开发和商业化用于患者局部治疗的新型综合药物和递送解决方案。该公司的治疗管道针对耳朵、鼻子和喉咙通道深处的组织,旨在提供持续的药物治疗。该公司的技术平台XTreo旨在通过单次给药,在持续时间内将药物精确、一致地直接输送到受影响的组织。该公司的候选产品LYR-210和LYR-220是生物可吸收聚合物基质,旨在通过简短、非侵入性的就诊程序进行给药,旨在为鼻窦通道提供长达六个月的连续药物治疗。治疗慢性鼻窦炎(CRS)。LYR-210和LYR-220中的治疗药物是糠酸莫米松。LYR-220是一种针对有和没有鼻息肉的CRS患者的研究性疗法。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
W. Bradford Smith | 66 | 2019 | Independent Director |
Gary M. Ansel | - | - | Member of Medical Advisory Board |
Martin Schillinger | - | - | Member of Medical Advisory Board |
Elazer R. Edelman | 65 | - | Member of Scientific Advisory Board |
I. Baumgartner | - | - | Member of Medical Advisory Board |
Robert S. Langer | 73 | 2006 | Member of Scientific Advisory Board |
George M. Whitesides | 83 | 2006 | Member of Scientific Advisory Board |
Renu Virmani | - | - | Member of Scientific Advisory Board |
Michael D. Dake | - | - | Member of Medical Advisory Board |
Mark Saltzman | - | - | Member of Scientific Advisory Board |
Konstantin Poukalov | 38 | 2020 | Independent Director |
Michael Seth Altman | 40 | 2018 | Independent Director |
William A. Gray | - | - | Member of Medical Advisory Board |
Robert S. Schwartz | - | - | Member of Scientific Advisory Board |
James Morley Anderson | 81 | - | Member of Scientific Advisory Board |
Mahmood K. Razavi | - | - | Member of Medical Advisory Board |
Stephen L. Hilbert | - | - | Member of Scientific Advisory Board |
Nancy L. Snyderman | 69 | 2020 | Independent Director |
James R. Tobin | 77 | 2022 | Lead Independent Director |
Edward Thomas Anderson | 70 | 2019 | Independent Director |
Maria Palasis | 58 | 2015 | CEO, President & Director |
Harlan W. Waksal | 70 | 2022 | Executive Chairman |
C. Ann Merrifield | 72 | 2019 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核